A profitable company with steady sales.
Facts from SEC filings, not a recommendation.
From ECBK's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
Move the sliders to your own view of ECBK. Starting points are the company's recent numbers (it isn't profitable yet, so the margin starts at a 10% guess).
Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.
Price chart by TradingView.
From annual reports filed with the SEC. Gross margin doesn't apply to banks and insurers, so it isn't scored. Not in this company's SEC data, so not scored: debt under half of equity, net margin 10%+. A checklist is a starting point for research, not a verdict.
Revenue and EPS as the company states them. Margins, cash flow and share count fill in with the 10-Q.
No open-market insider buys or sells in the last 90 days.
No trades to chart yet.
SEC filings of any kind. 50 means a normal week.
Institutions added 0.0% to their holdings. 32 bought, 16 sold. 2 quarters of net selling in a row.
No offerings, red flags or new big holders. Clean record.
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
40 shares at $17.89 avg ($17.85 to $17.92) · $716
5,832 shares at $11.80 · $69K
Source: SEC EDGAR filings. For informational purposes. Not investment advice.
Report a problem with this page